Mercado de intermediarios API de Asia-Pacífico: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de intermediarios API de Asia-Pacífico

El mercado de intermediarios API de Asia-Pacífico ha experimentado un crecimiento significativo debido a la alta carga de trastornos crónicos y el aumento de la población que envejece, que son los principales impulsores que impulsaron la demanda del mercado.                      

Data Bridge Market Research analiza que el mercado de intermediarios de API de Asia-Pacífico, que fue de USD 6.914,12 millones en 2022, se espera que alcance los USD 12.034,12 millones para 2030, y se espera que experimente una CAGR del 7,0% durante el período de pronóstico de 2023 a 2030. Los "intermedios de medicamentos veterinarios farmacéuticos" dominan el segmento de tipo de producto del mercado de intermediarios de API de Asia-Pacífico debido a una mayor demanda de API en todo el mundo. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de intermediarios API de Asia-Pacífico

Market Definition

Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others.

Asia-Pacific API Intermediates Market Dynamics

Drivers

• Growing Pharmaceutical Industry

The Asia-Pacific region has witnessed substantial growth in its pharmaceutical industry. Factors such as an aging population, increasing healthcare expenditures, and rising prevalence of chronic diseases drive the demand for pharmaceuticals, thereby boosting the API intermediates market.

• Rising Generic Drug Manufacturing

The region is a prominent hub for generic drug manufacturing. Generic drugs require a constant supply of API intermediates, as they offer cost-effective alternatives to brand-name medications. The expanding generic drug market is a significant driver of API intermediate’s demand.

• Increasing Contract Manufacturing

The trend of outsourcing drug manufacturing to contract development and manufacturing organizations (CDMOs) has gained momentum in the Asia-Pacific region. Pharmaceutical companies, particularly those engaged in research and development, often choose to partner with CDMOs to streamline their operations and focus on core competencies. CDMOs rely on a stable and reliable supply chain, which includes API intermediates suppliers. Ensuring a consistent flow of quality intermediates is vital for CDMOs to meet their client’s needs efficiently. This demand from CDMOs fuels the growth of API intermediates manufacturers.

Opportunities

• Development and Adoption of Biopharmaceuticals and Biosimilar

The Asia-Pacific region has seen a surge in the development and adoption of biopharmaceuticals and biosimilar. These complex molecules often require specialized API intermediates for their production. This presents an opportunity for manufacturers to cater to the specific needs of biopharmaceutical companies. Biopharmaceuticals include monoclonal antibodies, gene therapies, and cell-based therapies, which are gaining prominence in treating various diseases. Manufacturers can invest in the research and development of API intermediates tailored to biopharmaceutical applications.

• Emerging and Markets Expansion

Expanding into emerging markets within the Asia-Pacific region offers significant growth opportunities for API intermediates manufacturers. Countries in Southeast Asia, for instance, are experiencing increased healthcare spending and greater access to healthcare services. These emerging markets represent untapped potential for API intermediates, as pharmaceutical production and research activities expand to meet the growing healthcare needs of their populations. Establishing a presence in these markets can lead to increased demand for intermediates.

Restraints/Challenges

• Regulatory Challenges in API Production

The pharmaceutical industry is highly regulated to ensure patient safety and product quality. Compliance with various international and national regulations and quality standards is mandatory, making regulatory adherence a complex and expensive process. API intermediates manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and undergo rigorous inspections and audits to maintain compliance. Regulatory changes, such as updates to quality standards or new compliance requirements, can pose challenges for manufacturers. Meeting these requirements often requires significant investments in infrastructure, technology, and human resources.

• Competition from Low-Cost Producers

The Asia-Pacific region is home to countries known for their cost-effective manufacturing capabilities, such as China and India. These countries have a competitive advantage due to lower labor and operational costs. As a result, they can produce API intermediates at a lower price point than manufacturers in other regions. This intense price competition can squeeze profit margins for API intermediates manufacturers operating in higher-cost locations. To remain competitive, manufacturers must focus on factors such as product quality, innovation, and service differentiation.

This Asia-Pacific API Intermediates market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific API Intermediates Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2021, Vertellus has been acquired by the company, Pritzker Private Capital who partners with the middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered as leading company or provider of specialty chemicals in different sectors such as healthcare, food and agriculture, personal care, transportation and coatings, so PPC has made a partnership with the company. This helped the company Vertellus to increase their market growth which will drive revenues of the company.

Asia-Pacific API Intermediates Market Scope

The Asia-Pacific API intermediates market is segmented on the basis of type, product, therapeutic type, customers, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Veterinary Drug Intermediates Pharmaceutical
• Bulk Drug Intermediates

Product

• Bromo Compound
• O-Benzyl Salbutamol
• Hemisulfate
• Oxirane
• Bisoprolol Base
• Chiral PCBHP
• Pheniramine Base
• Chlorpheniramine Base
• Brompheniramine Base
• Mepyramine/Pyrilamine Base
• 6-Amino-1,3-Dimethyl Uracil
• Theofylline
• Acefylline
• Xanthine
• Nitriles
• Others

Therapeutics Type

• Autoimmune Diseases
• Oncology
• Metabolic Diseases
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Disorders
• Dermatology
• Urology
• Others

Customers

• Direct Users/Pharma Companies
• Traders/Wholesalers/Distributors
• Associations/Govt. Institutions/Pvt Institutions

End-Users

• API Manufacturer
• Finished Product Manufacturer

Canal de distribución

• Licitación directa
• Ventas al por menor
• Otros

Análisis y perspectivas regionales del mercado de intermediarios API de Asia y el Pacífico

Se analiza el mercado de intermediarios de API de Asia-Pacífico y se proporcionan información y tendencias del tamaño del mercado por tipo, producto, tipo terapéutico, clientes, usuarios finales y canal de distribución como se menciona anteriormente.

Los países cubiertos en el informe del mercado de intermedios de API de Asia-Pacífico son China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas y el resto de Asia-Pacífico (APAC).

China lidera el crecimiento de la región Asia-Pacífico y el segmento de intermediarios farmacéuticos/de medicamentos a granel domina en este país porque China es el mayor productor de principios activos farmacéuticos a nivel mundial. India es el país de más rápido crecimiento debido al aumento de las iniciativas gubernamentales para la producción de principios activos farmacéuticos.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de caso son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado de los intermediarios API en Asia-Pacífico

El panorama competitivo del mercado de intermediarios de API de Asia-Pacífico proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de intermediarios de API de Asia-Pacífico.

Algunos de los principales actores que operan en el mercado de intermediarios API de Asia-Pacífico son:

• Sanofi (Francia)
• Industrias Aarti Limited (India)
• Aurobindo Pharma (India)
• Laboratorios Divi Limited (India)
• HIKAL Ltd. (India)
• Sandoz International GmbH (Alemania)
• BASF SE (Alemania)
• Corporación Cambrex (Estados Unidos)
• AlzChem Group AG (Alemania)
• Vasudha Pharma (India)
• Anyang General Chemical Co., Ltd. (Corea del Sur)
• Sarex (India)
• Sandoo Pharmaceuticals and Chemicals Co., Ltd. (China)
• Atul Ltd. (India)
• Aceto (Estados Unidos)
• Supriya Lifescience Ltd. (India)
• Vertellus (Estados Unidos)
• Dishman Carbogen Amcis Ltd (Suiza/India)
• Grupo Ganesh (India)
• Levachem Company Limited (China)

SKU-60968